Carbidopa/oxytriptan - Evecxia
Alternative Names: EVX-101Latest Information Update: 02 Dec 2024
At a glance
- Originator Evecxia
- Class Antidepressants; Behavioural disorder therapies; Catecholamines; Hydrazines; Small molecules; Tryptamines
- Mechanism of Action Decarboxylase inhibitors; Serotonin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Depressive disorders; Obsessive-compulsive disorders
Most Recent Events
- 25 Nov 2024 Phase-I clinical trials in Obsessive-compulsive disorders (Adjunctive treatment)(PO) prior to November 2024 (Evecxia Pipeline, December 2024)
- 25 Jul 2024 Evecxia files patent protection for chemical synthesis of 5-hydroxytryptophan (5-HTP)
- 05 Oct 2023 9399661 - KDM updated, scientific data and HE added, trial initiation FE added